Rogier Rooswinkel Ph.D

Rogier Rooswinkel Ph.D General Information

Biography

Dr. Rogier Rooswinkel serves as General Partner at Forbion. He serves as a Board Member at Granite Bio. He serves as Board Member at Pheon Therapeutics, Achilles Therapeutics & Amphista Therapeutics. He also serves as Board Observer at Enterprise Therapeutics. He serves as Board Member at Tessellate Bio. He has a background in Medical Sciences, and in 2008 finished a Master of Oncology at the Free University in Amsterdam. In that period he also started an IT company. At the beginning of 2013, he received his Ph.D. degree Cum Laude from the University of Amsterdam for the work he performed at the Netherlands Cancer Institute in the groups of Prof. Dr. Jannie Borst and Prof. Dr. Marcel Verheij. In this period, he studied the mechanism of action of novel small molecule Bcl-2 inhibitors, their role in apoptosis induction, and their applicability to reduce chemo-and radiotherapy resistance in hematological malignancies. He serves as Board Member at LoQus23 Therapeutics. Rogier is responsible for the evaluation and structuring of new investment opportunities across all disease areas with an emphasis on oncology. He was among others closely involved in the investments in Rigontec, Replimune, Enterprise, KaNDy and the setting up of the university spin-out Catalym. He currently serves as a board member for Amphista, Catalym, and Tessellate and as a board observer for Enterprise and Escalier. Rogier joined Forbion in 2013. Prior to joining Forbion, Rogier worked as a post-doc at the Netherlands Cancer Institute (NKI), division of immunology. During his studies, Rogier was active as an independent website designer and founded an IT-company. In 2013 he received his PhD degree Cum Laude from the University of Amsterdam for the work he performed at the NKI. Before that, he received a Master's degree in Oncology at the VU University of Amsterdam.